These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 25670078)

  • 1. Emerging strategies for treating brain metastases from breast cancer.
    Kodack DP; Askoxylakis V; Ferraro GB; Fukumura D; Jain RK
    Cancer Cell; 2015 Feb; 27(2):163-75. PubMed ID: 25670078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib.
    Tomasello G; Bedard PL; de Azambuja E; Lossignol D; Devriendt D; Piccart-Gebhart MJ
    Crit Rev Oncol Hematol; 2010 Aug; 75(2):110-21. PubMed ID: 20004109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Therapies for Brain Metastases from Breast Cancer.
    Venur VA; Leone JP
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27649142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neratinib in ERBB2-Positive Brain Metastases.
    Pegram MD
    JAMA Oncol; 2016 Dec; 2(12):1541-1543. PubMed ID: 27077740
    [No Abstract]   [Full Text] [Related]  

  • 5. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
    Lewis Phillips GD; Nishimura MC; Lacap JA; Kharbanda S; Mai E; Tien J; Malesky K; Williams SP; Marik J; Phillips HS
    Breast Cancer Res Treat; 2017 Aug; 164(3):581-591. PubMed ID: 28493046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 in brain metastases: issues of concordance, survival, and treatment.
    Fuchs IB; Loebbecke M; Buhler H; Stoltenburg-Didinger G; Heine B; Lichtenegger W; Schaller G
    J Clin Oncol; 2002 Oct; 20(19):4130-3. PubMed ID: 12351617
    [No Abstract]   [Full Text] [Related]  

  • 7. Medical management of brain metastases and leptomeningeal disease in patients with breast carcinoma.
    Bowman KM; Kumthekar P
    Future Oncol; 2018 Feb; 14(4):391-407. PubMed ID: 29345149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Sanctuary Site: Options when Breast Cancer Metastasizes to the Brain.
    Krishnan M; Krishnamurthy J; Shonka N
    Oncology (Williston Park); 2019 Aug; 33(8):. PubMed ID: 31469897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer.
    Melisko ME; Glantz M; Rugo HS
    Nat Clin Pract Oncol; 2009 Jan; 6(1):25-33. PubMed ID: 18936791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A view on the landscape of breast cancer brain metastases.
    Malani R
    CNS Oncol; 2020 Sep; 9(3):CNS59. PubMed ID: 32990026
    [No Abstract]   [Full Text] [Related]  

  • 11. Activity of T-DM1 in Her2-positive breast cancer brain metastases.
    Bartsch R; Berghoff AS; Vogl U; Rudas M; Bergen E; Dubsky P; Dieckmann K; Pinker K; Bago-Horvath Z; Galid A; Oehler L; Zielinski CC; Gnant M; Steger GG; Preusser M
    Clin Exp Metastasis; 2015 Oct; 32(7):729-37. PubMed ID: 26303828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic approach to the management of HER2-positive breast cancer metastatic to the brain.
    Patil A; Sherbet GV
    Cancer Lett; 2015 Mar; 358(2):93-99. PubMed ID: 25529010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical predictors of long-term survival in HER2-positive metastatic breast cancer.
    Murthy P; Kidwell KM; Schott AF; Merajver SD; Griggs JJ; Smerage JD; Van Poznak CH; Wicha MS; Hayes DF; Henry NL
    Breast Cancer Res Treat; 2016 Feb; 155(3):589-95. PubMed ID: 26875184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?
    Teplinsky E; Esteva FJ
    Curr Oncol Rep; 2015 Oct; 17(10):46. PubMed ID: 26314739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
    Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
    Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting HER2 in brain metastases from breast cancer.
    Kirsch DG; Hochberg FH
    Clin Cancer Res; 2003 Nov; 9(15):5435-6. PubMed ID: 14654521
    [No Abstract]   [Full Text] [Related]  

  • 17. Updates on the management of breast cancer brain metastases.
    Lim E; Lin NU
    Oncology (Williston Park); 2014 Jul; 28(7):572-8. PubMed ID: 25144276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis.
    Charmsaz S; Doherty B; Cocchiglia S; Varešlija D; Marino A; Cosgrove N; Marques R; Priedigkeit N; Purcell S; Bane F; Bolger J; Byrne C; O'Halloran PJ; Brett F; Sheehan K; Brennan K; Hopkins AM; Keelan S; Jagust P; Madden S; Martinelli C; Battaglini M; Oesterreich S; Lee AV; Ciofani G; Hill ADK; Young LS
    BMC Med; 2020 Nov; 18(1):349. PubMed ID: 33208158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and cellular mechanisms underlying brain metastasis of breast cancer.
    Hosonaga M; Saya H; Arima Y
    Cancer Metastasis Rev; 2020 Sep; 39(3):711-720. PubMed ID: 32399646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.
    Hayashi N; Niikura N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Yamauchi H; Saji S; Iwata H
    Breast Cancer Res Treat; 2015 Jan; 149(1):277-84. PubMed ID: 25528021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.